广告
加载中

发布妆械联合解决方案 薇诺娜以医研实力铸就国货护肤标杆

石磊 2026-04-29 17:13
石磊 2026/04/29 17:13

邦小白快读

EN
全文速览

文章重点介绍了医美后皮肤屏障受损问题及科学护理方案,提供实用操作指南。

1. 医美后皮肤屏障受损问题:约68.3%消费者在医美项目后出现皮肤屏障受损,护理不当是主因,亟需科学解决方案。

2. 妆械联合实操步骤:术前使用妆字号功效护肤品(含神经酰胺、青刺果油等)强韧屏障;术后即刻用械字号医用敷料(含透明质酸、胶原蛋白等)冷敷保湿、促进愈合;恢复期引入妆字号舒缓产品维稳屏障。

3. 薇诺娜311屏障系列新品:包括屏障水、屏障霜和胶原次抛,专为医美前后和敏感肌设计,成分精简,测试显示能有效改善肌肤屏障、提升细腻度和弹润度。

4. 简化操作指南:薇诺娜发布《轻医美修护指南图鉴》,将有创/无创项目分为术前、术后即刻、术后短期、术后长期四阶段,提供易跟进的护理建议。

薇诺娜通过产品创新和品牌行动,引领医美护理市场,回应消费趋势。

1. 品牌营销策略:参与第七届敏感性皮肤高峰论坛,发布《敏感性皮肤光电治疗选择时机及围术期护理专家共识》和311屏障系列新品,提升品牌权威形象;联合发布《轻医美修护指南图鉴》,简化复杂理论,增强用户亲和力。

2. 产品研发逻辑:遵循NUTE原则(临床需求、独特机制、科技赋能、证据可信),新品如311屏障速修霜含极地PDRN、311屏障再生元和丝心蛋白,构建全面修护体系;以制药思路做护肤品,嵌入临床研究和循证医学。

3. 消费趋势与用户行为:医美后护理需求增长,用户追求科学安全方案;研究显示,使用薇诺娜妆械联合方案在射频治疗中能降低不良反应风险,维护屏障稳态,提升治疗效果,符合用户对功效可验证的需求。

4. 品牌核心基因:强调皮肤科学、药植科技、循证研究和高质品控,贝泰妮累计发表650余篇实证论文,覆盖多产品系列,支撑品牌专业领先地位。

行业新标准和事件提供增长机会与学习点,助力市场应对。

1. 政策解读与事件应对:《敏感性皮肤光电治疗选择时机及围术期护理专家共识》是国内首部敏感肌光电围术期共识,强调妆械联合策略,提供标准化操作规范;论坛发布科研激励基金,面向全国皮肤科医生,资助创新研究,卖家可借机参与合作。

2. 增长市场与消费需求机会:医美全周期护理市场空缺大,约68.3%消费者术后受损,需求增长明显;薇诺娜新品聚焦该场景,卖家可引入311屏障系列等产品,满足敏感肌和医美前后需求。

3. 可学习点与风险提示:薇诺娜妆械联合方案(妆械协同)降低不良反应风险,提升治疗效果,卖家可学习其模式;风险包括护理不当导致屏障受损,需强调科学指导。

4. 最新商业模式与合作:薇诺娜以“1+1>2”协同方案(妆械联合),覆盖术前、术后、恢复期;论坛促进中韩专家对话,卖家可探索国际趋势合作,如引入类似产品线。

产品生产设计和商业机会启示,推动高标准制造。

1. 产品生产需求:薇诺娜打造皮肤学级高标准工厂,构建全链条高规格品控体系,满足全周期护理品控要求;新品如311屏障系列强调成分精简和功效明确,生产需确保原料(如极地PDRN、丝心蛋白)质量和稳定性。

2. 设计需求与商业机会:产品设计基于临床需求,如专为医美前后和敏感肌修护开发;遵循独特机制(如311屏障再生元),工厂可借鉴NUTE原则,聚焦需求导向设计。

3. 推进数字化和电商启示:医美护理市场增长,薇诺娜通过学术论坛和指南发布推广产品,工厂可探索电商渠道,如简化产品线以适应在线销售;研究数据(如肌肤改善测试)可作为营销支撑,启示数字化品控管理。

行业趋势和新技术解决客户痛点,提供有效方案。

1. 行业发展趋势:妆械联合成为国际医美护理趋势,论坛首发皮肤稳态学理论,通过多维度干预维护皮肤平衡,推动行业科学化、规范化;敏感性皮肤高峰论坛成果丰硕,驱动中国皮肤健康生态发展。

2. 新技术与客户痛点:皮肤稳态学理论创新性提出,由何黎教授系统研究机制,解决术后皮肤屏障受损痛点(约68.3%消费者受影响);新技术包括光电围术期科学方案,术前提升耐受阈值,术后促进愈合。

3. 解决方案:薇诺娜妆械联合方案提供全面修护,如311屏障系列新品与械字号产品协同;研究证明,在射频治疗围术期使用该方案能有效降低风险,维护屏障稳态;服务商可借鉴指南图鉴,拆解复杂步骤为客户服务。

商业对平台需求和平台做法启示,优化运营管理。

1. 商业对平台需求:医美护理市场亟需标准化产品,如妆械联合方案要求平台提供可靠品控商品;消费者对全周期护理需求严格,平台需引入薇诺娜等高质品控产品,满足屏障修护等需求。

2. 平台最新做法与招商机会:薇诺娜通过高峰论坛发布新品和共识,平台可借机招商,如引入311屏障系列;平台运营可参考指南图鉴,简化用户操作步骤,提升体验。

3. 风向规避与运营管理:行业缺乏统一标准风险,平台需规避低质产品;薇诺娜的高标准工厂和品控体系提供启示,平台应强化供应链管理,确保产品安全可追溯;研究数据(如不良反应降低)可作运营支撑。

产业新动向和政策启示,探索商业模式创新。

1. 产业新动向与新问题:皮肤稳态学理论首发,由何黎教授基于稳态医学提出,系统研究皮肤平衡机制;新问题包括医美全周期护理缺乏标准、产品适配性不足,专家共识填补空白。

2. 政策法规建议和启示:践行“健康中国2030”战略,皮肤健康关乎生活质量;论坛发布科研激励基金,资助皮肤科医生创新研究,启示政策支持转化潜力项目。

3. 商业模式与案例:薇诺娜妆械联合产品矩阵覆盖医美全周期,商业模式以学术引领(如高峰论坛),结合循证研究(贝泰妮650余篇论文);案例显示,使用该方案在射频治疗中提升治疗效果,降低风险,研究者可分析其临床实践规范。

返回默认

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

The article highlights the issue of skin barrier damage after cosmetic procedures and provides scientific care solutions with practical guidelines.

1. Skin barrier damage after cosmetic procedures: Approximately 68.3% of consumers experience skin barrier damage post-procedure, primarily due to improper care, creating an urgent need for scientific solutions.

2. Practical steps for cosmetic-medical device combination: Pre-procedure, use cosmeceutical products (containing ceramides, Prinsepia utilis Royle oil, etc.) to strengthen the barrier; immediately post-procedure, apply medical device-grade dressings (containing hyaluronic acid, collagen, etc.) for cooling, moisturizing, and promoting healing; during recovery, introduce soothing cosmeceutical products to stabilize the barrier.

3. Winona's new 311 Barrier Series: Includes barrier toner, barrier cream, and collagen ampoules, specifically designed for pre/post-procedure and sensitive skin. With simplified ingredients, tests show effective improvement in skin barrier, texture refinement, and elasticity.

4. Simplified operational guide: Winona released the "Minimally Invasive Procedure Repair Guide Infographic," categorizing invasive/non-invasive procedures into four stages (pre-op, immediate post-op, short-term post-op, long-term post-op) with easy-to-follow care recommendations.

Winona leads the medical aesthetics care market through product innovation and brand initiatives, responding to consumer trends.

1. Brand marketing strategy: Participated in the 7th Sensitive Skin Summit, releasing the "Expert Consensus on Timing and Perioperative Care for Photoelectric Therapy in Sensitive Skin" and launching the 311 Barrier Series to enhance brand authority; co-published the "Minimally Invasive Procedure Repair Guide Infographic" to simplify complex theories and improve user engagement.

2. Product R&D logic: Adheres to the NUTE principle (Clinical Need, Unique Mechanism, Technology Empowerment, Trustworthy Evidence). New products like the 311 Barrier Rapid Repair Cream contain Arctic PDRN, 311 Barrier Regenerative Complex, and fibroin, building a comprehensive repair system; adopts a pharmaceutical approach to skincare, embedding clinical research and evidence-based medicine.

3. Consumer trends & user behavior: Growing demand for post-procedure care, with users seeking scientifically safe solutions; studies show Winona's cosmetic-medical device combination reduces adverse reaction risks in radiofrequency treatments, maintains barrier homeostasis, and improves efficacy, meeting demand for verifiable results.

4. Core brand DNA: Emphasizes skin science, botanical technology, evidence-based research, and high-quality control. Parent company Botanee has published over 650 empirical papers covering multiple product lines, supporting its professional leadership.

Industry new standards and events provide growth opportunities and learning points for market adaptation.

1. Policy interpretation & event response: The "Expert Consensus on Timing and Perioperative Care for Photoelectric Therapy in Sensitive Skin" is China's first perioperative consensus for sensitive skin, emphasizing cosmetic-medical device combination strategies and providing standardized protocols; the summit launched a research incentive fund for dermatologists nationwide, offering collaboration opportunities for sellers.

2. Growth market & consumer demand: Significant gap in full-cycle medical aesthetics care market, with ~68.3% of consumers experiencing post-procedure damage indicating clear demand growth; Winona's new products target this scenario—sellers can introduce the 311 Barrier Series to meet sensitive skin and peri-procedure needs.

3. Learnings & risk alerts: Winona's cosmetic-medical device combination reduces adverse reaction risks and improves treatment efficacy—sellers can adopt similar models; risks include barrier damage from improper care, necessitating emphasis on scientific guidance.

4. Latest business models & collaboration: Winona's "1+1>2" synergistic approach (cosmetic-medical device combination) covers pre-op, post-op, and recovery phases; the summit facilitated China-Korea expert dialogue—sellers can explore international trend collaborations, such as introducing similar product lines.

Product design and commercial opportunities inspire high-standard manufacturing.

1. Production requirements: Winona operates dermatology-grade high-standard factories with full-chain quality control systems meeting full-cycle care demands; new products like the 311 Barrier Series emphasize simplified ingredients and clear efficacy—production must ensure raw material (e.g., Arctic PDRN, fibroin) quality and stability.

2. Design needs & commercial opportunities: Product design based on clinical needs (e.g., specialized for peri-procedure and sensitive skin repair); follows unique mechanisms (e.g., 311 Barrier Regenerative Complex)—factories can adopt the NUTE principle for demand-driven design.

3. Digitalization & e-commerce insights: Growing medical aesthetics care market; Winona promotes products via academic forums and guides—factories can explore e-commerce channels, simplifying product lines for online sales; research data (e.g., skin improvement tests) supports marketing, inspiring digital quality control management.

Industry trends and new technologies address client pain points with effective solutions.

1. Industry trends: Cosmetic-medical device combination is an international trend; the summit debuted skin homeostasis theory, promoting multi-dimensional intervention for skin balance and driving scientific standardization; the Sensitive Skin Summit yielded significant outcomes, advancing China's skin health ecosystem.

2. New technologies & client pain points: Innovative skin homeostasis theory, systematically studied by Prof. He Li, addresses post-procedure barrier damage (~68.3% affected); new technologies include scientific perioperative photoelectric protocols—pre-op tolerance threshold enhancement and post-op healing promotion.

3. Solutions: Winona's cosmetic-medical device combination offers comprehensive repair (e.g., 311 Barrier Series synergy with medical device products); studies prove risk reduction and barrier homeostasis maintenance in radiofrequency perioperative use—service providers can adapt the guide infographic to simplify complex steps for clients.

Business demands on platforms and operational insights for optimization.

1. Platform demands: Medical aesthetics care market needs standardized products (e.g., cosmetic-medical device combinations require reliable quality-controlled goods); consumers demand strict full-cycle care—platforms must introduce high-quality products like Winona's to meet barrier repair needs.

2. Latest practices & merchant opportunities: Winona launched new products and consensus via the summit—platforms can leverage this for merchant recruitment (e.g., introducing the 311 Barrier Series); platform operations can reference the guide infographic to simplify user steps and enhance experience.

3. Risk avoidance & operations management: Industry lacks unified standards—platforms must avoid low-quality products; Winona's high-standard factories and QC systems inspire strengthened supply chain management for safety and traceability; research data (e.g., reduced adverse reactions) supports operations.

Industry trends and policy insights for exploring business model innovation.

1. Industry trends & new issues: Debut of skin homeostasis theory, proposed by Prof. He Li based on homeostasis medicine, systematically studying skin balance mechanisms; emerging issues include lack of standards for full-cycle medical aesthetics care and product adaptability—expert consensus fills gaps.

2. Policy recommendations & insights: Aligns with "Healthy China 2030" strategy—skin health impacts life quality; summit launched research incentive fund for dermatologists' innovation, suggesting policy support for translational projects.

3. Business models & case studies: Winona's cosmetic-medical device product matrix covers full medical aesthetics cycle, combining academic leadership (e.g., summits) with evidence-based research (Botanee's 650+ papers); case studies show enhanced treatment efficacy and risk reduction in radiofrequency therapy—researchers can analyze its clinical practice norms.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

【亿邦原创】近日,央视网的报道揭示了当下医美行业发展的焦虑:相关调研显示,约68.3%的消费者在医美项目后出现不同程度的皮肤屏障受损,护理不当是造成这一情况的重要原因。整个行业亟需建立一套科学、规范、可落地的医美全周期护理体系,回应大众诉求。

4月27日,第七届敏感性皮肤高峰论坛在上海中华艺术宫举行,此次论坛以“妆械联合 共筑皮肤稳态新范式”为主题,直面医美全周期皮肤护理缺乏统一标准、产品适配性不足等问题,重磅首发皮肤稳态学理论,为消费者带来了科学、安全、有效解决方案。

01

皮肤稳态学理论重磅首发,共探围术期妆械联合新范式

医美遵循“先破后立”的治疗逻辑,因此无论何种轻医美项目,都会对皮肤屏障稳态造成损伤。

过往,人们的术后护理往往只会使用“械字号”敷料。事实上,以妆械联合为手段,才能实现医美全周期“破”与“立”全周期管理的完整路径。

高峰论坛上,昆明医科大学第一附属医院、亚太皮肤屏障研究会副主席何黎教授在稳态医学概念的基础上,创新性提出皮肤稳态学,系统研究皮肤平衡稳态的机制,通过多维度干预来恢复、维护和增强这种平衡能力,从而维护皮肤长期健康与稳定,这一前沿理论为医美围术期管理提供了全新的学术框架。

基于皮肤稳态学理论,复旦大学附属华山医院任捷教授系统阐述了光电围术期妆械联合的科学方案。术前使用妆字号功效性护肤品(如含神经酰胺、青刺果油等成分)强韧屏障,提升皮肤对光电刺激的耐受阈值;术后即刻及急性期根据有创/无创类型,选用械字号医用敷料(含透明质酸、胶原蛋白等)进行冷敷、封闭保湿、促进创面愈合;恢复期逐步引入妆字号舒缓修护产品,持续维稳屏障,预防炎症后色沉。

论坛上,中韩皮肤学专家跨越国界深度对话,韩国延世大学医学院皮肤科学名誉教授李胜宪也强调,妆械联合是国际医美护理的趋势。

立足于敏感性皮肤光电治疗围术期科学管理的迫切临床需求,由众多权威专家共同编制的《敏感性皮肤光电治疗选择时机及围术期护理专家共识》在论坛上重磅揭幕。

这是国内首部聚焦敏感肌光电围术期护理领域的专家共识,其以妆械联合为核心应用策略,强调敏感性皮肤光电治疗的目标及介入时机,明确了敏感性皮肤光电围术期稳态管理路径,强调屏障修护在围术期的核心地位,将稳态理论转化为可操作的临床实践规范。

02

聚焦医美全周期护皮肤护理需求,薇诺娜屏障系列重磅上市

聚焦消费者围术期皮肤护理的现实需求,薇诺娜正式发布屏障系列新品311屏障水(屏障速修水)、311屏障霜(屏障速修霜)、311屏障胶原次抛轻盈版,为消费者带来了科学、安全、有效解决方案。

据悉,薇诺娜311屏障系列新品成分精简、功效明确,专为医美前后及敏感肌日常修护设计,与薇诺娜械字号产品形成“1+1>2”的协同方案。产品开发过程,遵循NUTE原则,围绕临床需求(Need)、独特机制(Unique)、科技赋能(Technology)和证据可信(Evidence)四大维度展开,确立了不可替代的专业领先地位。

其中,311屏障速修霜以取自高紫外线环境的极地PDRN、新打造的311屏障再生元和械品同源的丝心蛋白这三大核心成分,构建起了全面的修护体系。权威机构测试后的数据显示,311屏障速修霜有效改善肌肤屏障,并在细腻度、弹润度、光泽感和紧致度等多个维度为肌肤带来综合改善。

作为中国首个自主研发且通过临观验证的皮肤学级护肤品牌,自成立以来,薇诺娜始终坚持“以制药思路做护肤品”的研发逻辑,将临床研究、循证医学与安全验证嵌入产品全生命周期管理之中。

在上海市皮肤病医院进行的、针对敏感肌射频治疗围术期的研究成果表明,使用薇诺娜妆械联合护理方案在敏感性皮肤射频治疗围术期中展现出显著优势,能够有效降低术后不良反应风险,维护屏障稳态,助力面部年轻化效果,提升整体治疗效果与体验。

03

践行“健康中国2030”战略,薇诺娜以皮肤学级高质品控护航国民皮肤健康

捕捉到轻医美围术期修护场景机会的品牌众多,薇诺娜311屏障系列新品硬核产品力背后,是品牌“皮肤科学、药植科技、循证研究、高质品控”的核心基因。

从王牌单品特护霜到最新的屏障系列,薇诺娜持续以学术引领产品创新。薇诺娜母公司贝泰妮累计发表实证论文650余篇,覆盖特护、屏障、防晒、修白、医疗器械等多个系列产品,核心功效均有权威数据支撑,真正实现功效可验证、安全可追溯、效果可感知。

论坛上, 薇诺娜联合发布《轻医美修护指南图鉴》,它将复杂的“皮肤稳态学”和“妆械联合”方案,拆解为普通人能看懂、照着做的具体步骤——区分有创/无创项目,明确术前、术后即刻、术后短期、术后长期四个阶段的操作建议。

在生产端,薇诺娜打造了皮肤学级高标准工厂,构建起全链条高规格品控体系,满足了消费者对于全周期护理护肤品品控的严格要求,构建起全方位的品质壁垒。

作为一家以科研为驱动力,以责任为底色的品牌,薇诺娜正以多种形式助力皮肤健康领域的科学化、规范化发展。

2020年首届至今,薇诺娜承办的敏感性皮肤高峰论坛已成为国内敏感性皮肤领域规格最高、影响力最广、成果最丰硕的学术论坛,每年高峰论坛都集结了众多皮肤科学领域专家学者,不仅引领着敏感肌研究前沿,更驱动了中国皮肤健康生态的持续发展。

本届论坛,贝泰妮集团联合领域内核心学术期刊《中国皮肤性病学杂志》发布「损容性皮肤问题科研激励基金」,面向全国皮肤科医生及科研人员,资助具有创新性和临床转化潜力的研究项目,薇诺娜以引领者姿态助力皮肤建立事业发展。

皮肤健康是“2030健康中国”战略中关乎人民生活质量的重要一环。从填补行业标准空白到坚守科学实证,从高标准品控到核心产品落地,薇诺娜积极践行“健康中国2030”战略,以专业力量引领护肤未来,薇诺娜妆械联合产品矩阵,覆盖医美全周期护理需求,让“皮肤越用越健康”成为现实。

亿邦持续追踪报道该情报,如想了解更多与本文相关信息,请扫码关注作者微信。

文章来源:亿邦动力

广告
微信
朋友圈

FAQ回顾

什么是医美术后皮肤屏障受损的主要问题?

根据相关调研,约68.3%的消费者在医美项目后会出现不同程度的皮肤屏障受损,护理不当是主要原因,行业亟需建立科学规范的医美全周期护理体系。

什么是“妆械联合”方案?

“妆械联合”指在医美围术期,结合使用“妆字号”功效性护肤品和“械字号”医用敷料的科学护理方案。术前用妆品强韧屏障,术后用械品促进愈合,恢复期再用妆品维稳,实现全周期管理。

薇诺娜311屏障系列新品有哪些核心特点?

薇诺娜311屏障系列专为医美前后及敏感肌修护设计,遵循NUTE研发原则,包含屏障水、屏障霜和胶原次抛。其屏障霜含极地PDRN、311屏障再生元等核心成分,经权威测试可有效改善肌肤屏障与综合肤质。

这么好看,分享一下?

朋友圈 分享

APP内打开

+1
+1
微信好友 朋友圈 新浪微博 QQ空间
关闭
收藏成功
发送
/140 0